

Substitute for form 1449A/PTO			Complete if Known		
(Revised 10/2001)				Application Number	09/930,905
INFO	MATION	DISCLO	STIDE	Filing Date	August 16, 2001
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	Christopher T. Privalle	
	(Use as many sheep as necessary)		Group Art Unit	1653	
(1752 Its industry Intelligence Intelligence)		Examiner Name	(not yet assigned)		
Sheet	1 1	of	1	Attorney Docket Number	35780/238028 (5780-4)

		U, S	, PATENT DOC	UMENTS		
		FOREIG	GN PATENT DO	CUMENTS		
Examiner Inivials	Cile No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Pajentes or Applicant of Cited Document	Pogea, Columns, Lines, Where Relevant Possuges or Relevant Figures Appear	Clos/Sibel
SR	45	WO 90/15613	12/27/1990	Rorer International		
8n	46	EP 0 156 961 A2	10/09/1985	Biotest Pharma GMBH		
_						

Exuminer Initials	Cite No.	OTHER PRIOR ART - NON PATE Include name of the author (in CAPITAL LETTER magazine, journal, serial, symposium, catalog, etc., country where published.	S), title of the article (when appropriate).	title of the item thook	т
					-
xaminer ignature	J	effrey Russel	Date Considered	March 7, 200	3

^{*} Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (Revised 10/2001)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

	Complete if Known		1	
Application Number	09/930,905		1	
Filing Date	August 16, 2001	2 2		•
First Named Inventor	Privalle	Caro	L_{i}	
Group Art Unit	1653	1/2 Y		_
Examiner Name	(not yet assigned)	C		M
Attorney Docket Number	<u>35780/238028</u> (5780-4)	7	10	
		9	_	

	U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	<u>Document Number</u> Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures		
KR	1	US -4,301,144	11-17-1981	Iwashita <i>et al</i> .	Whole document 5 14/6		
832	2	US -4,412,989	11-01-1983	Iwashita et al.	Whole document 5 30/385		
Tel	3	US - 4,529,719	07-16-1985	Туе	Whole document 517/6		
XX	4	US - 4,670,417	06-02-1987	Iwasaki et al.	Whole document 514/6		
SIL	5	US - 4,826,811	05-02-1989	Sehgal et al.	Whole document 5/4/6		
5/2V	6	US – 5,084,558	01-28-1992	Rausch et al.	Whole document 5'36/385		
XIC	7	US – 5,194,590	03-16-1993	Sehgal et al.	Whole-document 5 30/385		
YR.	8	US – 5,217,648	06-08-1993	Beissinger et al.	Whole document 514/6		
XX.	9	US - 5,234,903	08-10-1993	Nho et al.	Whole document 5/4/6		
M	10	US – 5,264,555	11-23-1993	Shorr et al.	Whole document 530/285		
XX	11	US - 5,281,579	01-25-1994	Estep	Whole document 514/6		
ST	12	US - 5,296,465	03-22-1994	Rausch et al.	Whole document 517/6		
\$V	13	US - 5,312,808	05-17-1994	Shorr et al.	Whole document 514/6		
1885 T	14	US - 5,386,014	01-31-1995	Nho et al.	Whole document Sic/385		
XI	15	US – 5,439,591	08-08-1995	Pliura et al.	Whole document 530/385		
YRR	16	US - 5,464,814	11-07-1995	Sehgal et al.	Whole document 5/4/6		
Ser	17	US – 5,478,805	12-26-1995	Shorr et al.	Whole document 517/6		
XX	18	US - 5,545,328	08-13-1996	Pliura et al.	Whole document 530/385		
822	19	US - 5,606,025	02-25-1997	D'Agnillo <i>et al</i> .	Whole document 530/385		
MI	20	US – 5,741,894	04-21-1998	Azari et al.	Whole document-5'30/385		
HIL	21	US - 5,840,701	11-24-1998	Hsia	Whole document 514 21		
X	22	US - 5,905,141	05-18-1999	Rausch et al.	Whole document 5 36/385		
9n	23	US - 5,998,361	12-07-1999	Bucci et al.	Whole document 5/1/2		
Examiner Signature	一 ;	Jeffrer E. Awsel		Date Considered	Merci 4,2003		

^{*} Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PATERIT & TRACE

Substitute for form 1449A/PTO (Revised 10/2001)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

_	(wo many and	cas as necessary)	
Sheet	3	of	3

	Complete if Known
Application Number	09/930,905
Filing Date	August 16, 2001
First Named Inventor	Privalle
Group Art Unit	1653
Examiner Name	(not yet assigned)
Attorney Docket Number	35780/238028 (5780-4)

			93
	r	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	0
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
JUL	36 -¥	Ll, H., et al., "Polynitroxylation Neutralizes the Hypertensive Effect of αα-Crosslinked Hemoglobin without Affecting Nitric Oxide Scavenging," 6 th Annual Meeting of the Oxygen Society, November 18-22, 1999, Abstract No. 234.	et
STR	37 Ø	MAO, G. et al., "Superoxide Dismutase (SOD)-Catalase Conjugates, Journal of Biological Chemistry, January 1993 pp. 416-420, Vol. 268(1), The American Society for Biochemistry and Molecular Biology, Inc., USA.	,
Jr_	38	PRIVALLE, C., et al., "Pyridoxalated Hemoglobin Polyoxyethylene: A Nitrio Ovido Service Privalence of the Privalence of	
RL	39 .	PRIVALLE, C., et al., "Pyridoxalated Hemoglobin Polyoxyethylene(PHP): A Nitric Oxide Scavenger With Antioxidant Properties," 4th Annual Meeting of the Oxygen Society, 1997, USA.	
	40	PRIVALLE, C., et al., "Pyridoxalated Hemoglobin Polyoxyethylene (Php) - A Modified Hemoglobin Therapeutic With Sod-Catalase Activity," 6 th Annual Meeting of the Oxygen Society, November 18-22, 1999, Abstract No. 254.	:
JR	414	QUEBEC, E. and CHANG, T., "Superoxide Dismutase and Catalase Cross-Linked to Polyhemoglobin Reduces Methemoglobin Formation <i>In Vitro</i> ," <i>Art. Cells. Blood Subs., and Immob. Biotech.</i> , 1995, pp.693-705, Vol. 23(6), Marcel Dekker, Inc.	
R	42	RAZACK S., et al., "Crosslinked Hemoglobin-Superoxide Dismutase-Catalase Scavenges Free Radicals in a Rat Model of Intestinal Ischemia-reperfusion Injury," 1997, Art. Cells, Blood Subs. and Immob. Biotech. pp. 181-192, Vol. 25(1&2), Marcel Dekker, Inc.	
M	43	SATO, et al., "Synthesis and Characterization of Superoxide Dismutase-Deferoxamine Conjugate Via Polyoxethylene: A New Molecular Device for Removal of a Variety of Reactive Oxygen Species", Bioconjugate Chem., 1995, pp. 249-254, Vol. 6(3), American Chemical Society, USA.	
32	44	TALARICO, T., et al., "Chemical Characterization of Pyridoxalated Hemoglobin Polyoxyethylene Conjugate," BBA, January 2000, pp. 53-65, Vol. 1476, Elsevier Science, BV.	
		·	
niner ture	Tet	Treamer considered Date Considered March 4.20	

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2110048v1

September 24,2003

€ E 10%	\$
0 1700	Substitute for form 14 (Revised 10/2001)
FEB	FORMAT
PATERIT & TRAC	STATEMEN

449A/PTO

TION DISCLOSURE NT BY APPLICANT

any sheets as necessary)

		•	
Sheet	2	of	3

	Complete if Known			2	
Application Number	09/930,905	<u> </u>	`	47	
Filing Date	August 16, 2001	6	1	\leftarrow	
First Named Inventor	Privalle	1/2	8	4	
Group Art Unit	1653	7	. 7	· ·	7
Examiner Name	(not yet assigned)	-//	Ž.	-	N
Attorney Docket Number	<u>35780/238028</u> (5780-4)	•	9,	6.	

				Po)
		OTHER PRIOR ART – NON PATENT LITE	RATURE DOCUME	ENTS	2
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of th magazine, journal, serial, symposium, catalog, etc.), date, page(s country where published.	e article (when appropriate)	title of the item (book	Т
De	24 *	AZARI, M., et al., "Diaspirin Crosslinked Hemoglobin (DCLH) Manufactured under GMP Requirements for Clinical Studies," App. 701-708, Vol. 22(3).	btm): Characterization of the Art. Cells, Blood Subs., and In	Process and the Product nmob. Biotech., 1994,	
In	25 d	BECHTEL, M., et al., "Virus Removal or Inactivation in Hemog Detergent/Solvent Treatment," Biomater. Artif. Cells Artif. Orga	globin Solutions by Ultrafiltra ans, 1988, pp. 123-128, Vol.	ition or 16(1-3).	
An	26	BONE, H., et al., "Pyridoxalated Hemoglobin Polyoxyethylene (Septic Sheep," J. Appl Physiol, 1998, pp. 1991-1999, Vol. 84, A	Conjugate Reverses Hyperdy American Physiological Socie	namic Circulation in ty, USA.	
John	27 ₽	CHANG, T., " Future Prospects for Artificial Blood", TIBTECH, Trends Journals, UK.	, February 1999, pp. 61-67, V	ol. 17(2), Elsevier	
SR	28 -{	D'AGNILLO, F. and CHANG, T., "Polyhemoglobin-Superoxide Antioxidant Properties," <i>Nature Biotechnology</i> , 1998, pp. 667-67	e Dismutase-Catalase as a Blo 71, Vol.16.	od Substitute with	
Jan .	29	D'AGNILLO,F. and CHANG, T. "Reduction of Hydroxyl Radica Reperfusion Injury Using Crosslinked Hemoglobin-Superoxide I and Immob. Biotech., 1997, pp. 163-180, Vol. 25, Marcel Dekker	Dismutase-Catalase " 1997 A	nb Model of Ischemia- rt. Cells, Blood Subs.	
JRL-	30-	-D'AGNIELO, Fand CHANG, T., "Cross-Linked Hemoglobin-S -Derived Free Radicals and Prevents Methemoglobin Formation a Immob. Biotech., 1993, pp. 609-621, Vol. 21(5), Marcel Dekker,	nd Iron Release," 1993. Rion	se Scavenges Oxygen nat., Art. Cells, &	
&r	31	D'AGNILLO, F. and CHANG, T., "Crosslinked Hemoglobin-Sup Associated Free Radical Events in Models of <i>In Vitro</i> and <i>In Vivo</i> International Symposium on Blood Substitutes, 1996, Vol. 24(4)	Orridativa Chara B 41	Reduces Hemoprotein- from the VI	
M	32	ESTEP, T., et al., "The Purification of Hemoglobin Solutions by land Conference, 1989, pp. 325-338, Alan R. Liss, Inc.		nth Ann Arbor	
In	33	FARMER, M., et al., "Validation of Virus Inactivation by Heat Tr Crosslinked Hemoglobin," 1992, Biomater. Artif. Cells Immobili.	reatment in the Manufacture zation Biotechnol., pp. 429-	of Diaspirin 433, Vol. 20.	
JR	34	HIGHSMITH, F., et al., "An Improved Process for the Production Biologicals, 1997, pp. 1-12, Vol. 25, The International Association	n of Sterile Modified Haemog n of Biological Standardization	lobin Solutions," on, USA.	
M	35	IWASHITA, Y., "Hemoglobin Conjugated with Polyoxyethylene" Wiley and Sons Ltd.	", Artificial Red Cells, 1995,	pp. 151-176, John	
Examiner	7		Date		
Signature		ette E. Russe	Considered	March 7, 2003	1

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.